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Abstract 
Over the last two decades there has been a renaissance in the pipeline of new drugs targeting malaria, with the 
launch of new products that help save the lives of children throughout the world. In addition, there is a wealth of 
new molecules both entering and progressing through clinical development. These bring hope for a new generation 
of simpler and more effective cures that could overcome the emerging threat of drug resistance. In addition, there 
is hope that some of these medicines will have prophylactic activity and can be used to protect vulnerable popula-
tions, given the absence of a highly effective vaccine. Switzerland has played a key role in the development of these 
medicines. First, the country has a long history of understanding the biology of parasites and the pharmacology of 
drug responses through the leadership of the Swiss Tropical and Public Health Institute in Basel. Second, the highly 
successful Swiss pharmaceutical industry brings, beyond excellence, a strong interest in neglected diseases, build-
ing on work at Hoffmann-La Roche in the last century and with more recent products from Novartis and other Swiss 
companies. Third, the emergence of product-development-partnerships, in this case led by the Medicines for Malaria 
Venture, based in Geneva, has helped to catalyze the development of new medicines and bring the community 
together within Switzerland and beyond. Finally, this progress would not have been possible without the engage-
ment of the Swiss people and the support of the federal government through the Swiss Agency for Development 
and Cooperation (SDC), the State Secretariat of Education, Research and Innovation (SERI) and the Swiss Republic and 
Canton of Geneva.
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Background
Malaria is caused by protozoan parasites that are trans-
mitted by mosquitoes (See Figs. 1 and 2 for the parasite’s 
life cycle, and [1]). Malaria remains one of the deadliest 
infectious diseases, with an estimated 435,000 deaths in 
2017, in spite of a decrease by 20% between 2010 and 
2017 [2, 3]. Switzerland’s successes in the fight against 
malaria are based on a variety of circumstances, some of 
which have deep historical roots.
First, as part of the country’s long-standing commit-
ment to international cooperation, Geneva has hosted 
the World Health Organization (WHO) since its incep-
tion in 1946. Along with other organizations within the 
United Nations, the WHO monitors global health needs 
and sets priorities and treatment guidelines, including for 
malaria. The WHO maintains close links with the Inter-
national Red Cross that was founded by Henry Dunant in 
the same city, in 1863.
Second, the country has a longstanding excellence 
in science. Among countries with over 1  M inhabit-
ants, Switzerland has the highest per-capita ranking 
of science Nobel Prizes. High-quality malaria research 
is being carried out at universities in Basel, notably 
the Swiss Tropical and Public Health Institute (Swiss 
TPH), Geneva, Lausanne, Berne, Lugano and Zurich 
(Fig. 3), with over 270 ‘Swiss’ scientific publications in 
2017 (as listed by Scopus, Elsevier B.V., based on the 
corresponding authors’ addresses). Work at Univer-
sities is aimed at a better understanding of malaria, 
including new targets and small molecules, but also 
the immunology of the disease. Important work in the 
Open Access
Malaria Journal
*Correspondence:  wellst@mmv.org 
1 Medicines for Malaria Venture, Route de Pré Bois 20, 1215 Geneva, 
Switzerland
Full list of author information is available at the end of the article
Page 2 of 7Hooft van Huijsduijnen et al. Malar J           (2019) 18:94 
last area is done by the team of Prof. Lanzavecchia at 
the University of Lugano [4, 5]. Such work helps in the 
development of better vaccines, but may also lead to 
therapeutic antibodies [6].
Third, Switzerland is a leader of pharmaceutical inno-
vation; in 2017 it exported $41 billion worth of medi-
cines, ranking second among countries (of any size; [7]). 
As further exemplified below, several of these highly suc-
cessful companies, notably Novartis, are actively engaged 
in malaria, a disease generally considered of humanitar-
ian rather than investor interest.
Fourth, in order to join forces between commercial 
drug discovery entities and not-for-profit organizations 
the innovative public private partnership (PPP) model 
for malaria was pioneered in Switzerland by Medicines 
for Malaria Venture (MMV) and later pursued by Drugs 
for Neglected Diseases Initiative (DNDi)—organizations 
both based in Geneva. Such partnerships are essential to 
advance new potential medicines through clinical devel-
opment, aligned with the global needs (the target com-
pound profiles [6, 8, 9] and the eradication agenda [10]) 
for malaria.
Fifth, Switzerland has traditionally been open to 
attracting talent. It ranks significantly higher than its 
Fig. 1 An Anopheles mosquito taking a human blood meal. Photo 
credit: Mary Soan, SMG Photo Contest
Fig. 2 Schematic overview of stages (A–G top left) in the malaria parasite’s (Plasmodium) lifecycle. The Z-axis (above the plane) measures parasite 
numbers
Page 3 of 7Hooft van Huijsduijnen et al. Malar J           (2019) 18:94 
neighbours (Germany, France and Italy; http://tinyu 
rl.com/zaubz gw) in its proportion of foreign-born indi-
viduals. Switzerland is playing an active and strategic role 
on the global level to promote health as a global public 
good and a universal human right. The Swiss Agency for 
Development and Cooperation (SDC) has been a strong 
supporter to MMV’s mission since its inception in 1999, 
for which MMV is extremely grateful. MMV has been 
specifically focused on discovering, developing and deliv-
ering new medicines for malaria.
Switzerland’s role in anti‑malarials available today
The present pipeline of candidate drugs for malaria, and 
approved medicines, is shown in Fig.  4, with pipeline 
molecules from Swiss-based Pharma companies Novartis 
and Actelion, and preclinical candidates from the Swiss 
TPH (Swiss Tropical and Public Health Institute). Along 
with the approved medicines, this Figure illustrates the 
past and present engagement of Swiss-based R&D.
Mefloquine (Lariam) is an anti-malarial that was dis-
covered and developed in the 1970s by the Walter Reed 
Army Institute for Medical Research in the U.S., in a 
response to the numerous casualties from the disease—at 
one time, 1% of combat troops per day—during the war 
in Vietnam. Outside its use for the military, mefloquine 
was marketed worldwide by Hoffmann-La Roche, based 
in Basel. These days, mefloquine is mainly used as part 
of a fixed-dose combination (FDC) with artesunate, pro-
vided by CIPLA, an Indian-based company. This FDC 
was originally developed in collaboration with the Swit-
zerland-based DNDi.
DNDi also co-developed, with Sanofi, a new FDC for 
artesunate-amodiaquine (AS-AQ/Winthrop®), specifi-
cally formulated and packaged for use in children [11], 
with the PPP model for late-stage drug development.
Sulfadoxine–Pyrimethamine (Fansidar) was developed 
in the 1960s, also by Hoffmann-La Roche, after resist-
ance against the individual components severely limited 
their usefulness. Sulfadoxine–pyrimethamine is not used 
widely anymore for the treatment of malaria, outside of 
some states in India, where it remains since 2008 as part 
of the standard of care as a combination therapy with 
artesunate [12]. However, it has enjoyed a renaissance 
as part of a programme called Seasonal Malaria Chemo-
prevention (SMC). Children in parts of the world where 
malaria outbreaks occur regularly during a season, such 
as in Africa’s Sahel region, receive a full course of treat-
ment of sulfadoxine–pyrimethamine plus amodiaquine 
once each month through the rainy season. The WHO 
estimates that in 2016, 16 million children under 5 years 
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old were protected, with dramatic effects on morbid-
ity and mortality. The drug used in these studies is now 
manufactured by a Chinese company, Guilin Pharma-
ceuticals. Swiss companies driving innovation, and then 
sharing the market responsibilities with other companies 
once treatment volumes grow is a common theme.
Artemether–lumefantrine is also known as  Coartem® 
and Coartem-D®. Novartis, also based in Basel, has taken 
a leadership role in the development of this new arte-
misinin-based FDC for the treatment of uncomplicated 
malaria (such artemisinin-based combination therapy is 
usually abbreviated as ACT). Artemisinin was originally 
discovered in the 1970s as the active ingredient in the 
herb sweet wormwood (Artemisia annua) by Youyou Tu 
at the Chinese Military Academy of Sciences, who shared 
a 2015 Nobel Prize for her work [13]. In the same ‘Pro-
ject 523’ the Chinese developed lumefantrine as a next 
generation treatment, based on the original quinine/
chloroquine/plasmochin scaffold. Lumefantrine was in-
licensed by Novartis (then Ciba) in 1992, and developed 
as an FDC. The combination is an important step for-
wards in public health, since it avoids the possibility that 
a patient takes only one of the drugs, which is seen as a 
potential cause of resistance generation. Later, in collabo-
ration with MMV, Novartis developed a child-friendly, 
dispersible, taste-masked sweetened version, which 
has since been launched under the brand name Coar-
tem  Dispersible®. To date, almost 1000 million doses of 
artemether–lumefantrine have been supplied by Novartis 
at an affordable price to countries, of which over 350 mil-
lion are in the paediatric dispersible form. In doing so, 
they created a viable market, where generic companies 
are now supplying the majority of treatments.
The road to new products: new endoperoxides
Although ACT has been the mainstay of public health 
policy over the last decade [1, 14], the early days of arte-
misinin use were complicated by extreme price fluctua-
tions, caused by difficulties in estimating supply needs, 
and also the 18-month lag time needed to grow new 
Artemisia crops, until the active ingredient could be har-
vested. The cost-effective synthesis of artemisinin has 
always proved enormously problematic because of the 
molecule’s highly unusual endoperoxide structure. In 
Fig. 4 The global portfolio of anti-malarial medicines (development pipeline and approved products). For definitions of the target compound 
profiles (TCPs) and target product profiles (TPPs) see [6, 8, 9]. 60P, 60° Pharmaceuticals; DNDi, Drugs for Neglected Diseases initiative; GSK: 
GlaxoSmithBeecham; ITM, Institute of Tropical Medicine; MMV, Medicines for Malaria Venture; U.: University. See the MMV website (http://www.mmv.
org) for updated version of this Figure
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2002, MMV, the Swiss TPH along with Jonathan Ven-
nerstrom at the University of Nebraska, Hugues Matile at 
Hoffmann-La Roche in Basel, Heinrich Urwyler at Basilea 
Pharmaceutica in Basel, and Sue and Bill Charman at 
Monash University in Melbourne set up a collaboration 
to develop next-generation endoperoxides. The goal was 
to find a new molecule that was as active as artesunate 
(an injectable artemisinin derivative), with a fully syn-
thetic scheme, allowing a low cost of goods, and also the 
potential to increase the duration of action of the treat-
ment. The first compound to emerge from this highly 
fruitful collaboration was OZ277 (arterolane; [15, 16]). 
This was taken into full clinical development, and then 
partnered with the Indian company Ranbaxy. OZ277 has 
since been launched as a combination with piperaquine 
as Synriam™, and is used to treat an estimated 1 million 
patients per year, primarily in India.
The Swiss-Australian-American collaboration also con-
tinued to develop the scaffold further, producing a sec-
ond-generation clinical candidate, OZ439 (artefenomel; 
[17, 18]). This molecule has the advantage of a much 
longer plasma residence time, and higher exposure, with 
the potential of being part of a single-dose cure. Current 
anti-malarial therapies require 3  days of treatment, and 
a single-dose cure is seen as having a very clear advan-
tage of allowing directly observed therapy; [8]. The mol-
ecule has passed Phase Ia [19], Phase Ib ([20] in malaria 
infected volunteers, and Phase IIa studies (monotherapy 
in patients). It is now in Phase IIb clinical trials.
With the emergence of artemisinin resistance, associ-
ated with the newly identified kelch13 mutations [21–23], 
there was a fear that these new endoperoxides would not 
retain activity against these mutant strains. However, 
careful analysis of the in vitro data suggests that while the 
compounds were optimized to increase stability in the 
presence of ferrous iron  (Fe2+) their action against the 
artesunate-resistant mutant strains was retained [24].
A third-generation endoperoxide, OZ609 (now called 
MMV052), has also been identified. This has the poten-
tial to be fully active against artemisinin-resistant strains 
[25]. MMV052 is currently in pre-clinical safety testing, 
with a view to starting human studies in 2019.
Phenotypic screening finds new starting points
One of the transformative events of the last decade has 
been the emergence of high-content phenotypic screens 
that look for inhibitors of blood-stage infection [26]. 
Until these became widely available in 2007–8, Swiss 
TPH was the reference centre for WHO/TDR (the Spe-
cial Programme for Research and Training in Tropi-
cal Diseases) testing, with manual assays allowing the 
evaluation of around 10,000 compounds per year. The 
development of ultra-high throughput assays by Case W. 
MacNamara and Elizabeth Winzeler (at the time part of 
Novartis’ Genome Research Foundation in San Diego), 
allowed this number to be increased to several million 
per year. Novartis was, therefore, the first company to 
test their entire deck of compounds for potential malaria 
starting points [27], and set a trend that was followed by 
GlaxoSmithKline [28], St. Jude Children’s Research Hos-
pital in Memphis Tennessee [29], The Eskitis Institute, 
Brisbane [30] and others, such as AstraZeneca, Pfizer, 
Sanofi and several Japanese companies. The early results 
were impressive, showing a 0.5% hit rate of compounds 
with an  IC50 below 2  μM as cut-off, leading to almost 
30,000 starting points [26].
From these early starting points, Novartis (through its 
Institute for Tropical Diseases in Singapore led by Alex 
Matter, as well as the Genomics campus, and the central 
facilities in Basel) was able to partner with Swiss TPH, 
MMV and the UK’s Wellcome Trust for the identification 
and work-up of two new classes of compounds: KAE609 
and KAF156.
KAE609 (cipargamin; formerly NITD609) is a new syn-
thetic anti-malarial spiroindolone analogue that rapidly 
cleared both major malaria parasites, Plasmodium falci-
parum and Plasmodium vivax, in patients when tested in 
a Phase IIa study [31, 32]. Like all such new molecules it 
is further tested in the clinic in combinations, to prevent 
(delay) the emergence of resistance and to reduce the risk 
of recrudescence in patients. KAF156 also belongs to a 
completely new class of anti-malarial agents (imidazolo-
piperazines; [33]). It recently completed Phase I [34, 35] 
and Phase IIa [36] monotherapy studies.
The results of these massive screening campaigns also 
benefit drug discovery for other infectious diseases; as 
part of its open-source drug discovery activities MMV 
has made key compound sets available for screening on 
other pathogens, sending out 400 compounds in ‘Malaria 
Box’ copies to over 200 research teams and overseeing 
the data reporting [37]. This highly successful initiative 
was followed by the Pathogen Box [38, 39], and in Janu-
ary 2019, MMV and DNDi announced the public release 
of the Pandemic Response Box, drug screening sets 
against an increasingly wider circle of human pathogens.
ACT-451840 is another anti-malarial candidate with 
novel structure, discovered in a fully Swiss collaboration 
between Actelion and the Swiss TPH ([40, 41]; Actelion 
Pharmaceuticals Ltd is based in Allschwil, Switzerland). 
The molecule was well tolerated in a Phase Ia study [42], 
and with further support from MMV demonstrated effi-
cacy in volunteers carrying experimental malaria infec-
tion [43].
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Underpinning the technology
Beyond the molecules and clinical candidates where 
Switzerland has taken the leading role, Swiss organiza-
tions have also provided critical resources for most of 
the early discovery portfolio. One key example in this 
area is the development of MMV048 (MMV390048; 
[44], a phosphoinositol (PI) 4-kinase inhibitor discov-
ered by an international team led by Dr Kelly Chibale 
of the University of Cape Town, South Africa. Here, the 
Swiss TPH played a key role in the early characteriza-
tion of the compound series both in  vitro and in  vivo 
in the murine models [45]. However, the work to facili-
tate a technology transfer of the assays to South Africa 
is equally important, allowing the South African con-
sortium to become fully independent after the first few 
years and pursue the discovery of additional new mol-
ecules [46].
The role of the Swiss-supported clinical centre in Baga-
moyo, Tanzania, is another example of this support and 
empowerment. The Bagamoyo centre is a branch of the 
Ifakara Health Institute (IHI) that emerged from the 
Swiss Tropical Institute Field Laboratory created in the 
middle of the last century by funding from the Basel 
Foundation and Swiss TPH. Its leadership has always 
centred on local empowerment, and the centre has been 
become one of the few Phase I trial sites in sub-Saharan 
Africa and, overall, one of the most productive clinical 
trial sites in Africa, directly and indirectly contributing to 
a decrease in malaria.
Conclusions
The war against malaria takes place in battles that are 
hard won (with new drugs and other interventions 
through integrated approaches) but also lost (emerging 
resistance, mismanagement of resources, lapses in local 
healthcare under economic hardship or strife; [47]); out-
witting the enemy requires continuous effort. Switzer-
land’s successes in helping discover and introduce new 
medicines for this disease are driven by a number of cir-
cumstances: the country’s scientific excellence and open-
ness; its highly innovative pharmaceutical industry with a 
willingness to also invest in ‘diseases of poverty’; its long-
standing commitment to promoting universal health as a 
basic human right; and its hosting of both international 
organizations that pursue this aim as well as not-for-
profit PPPs that have the expertise to align efforts in this 
area.
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